Abstract 91P
Background
Immune Checkpoint inhibitors (ICI) administration at home is considered as a development priority by the French society of cancer immunotherapy and French government with “ma santé 2022” program. The study objective was to analyze the territorial development of ICI infusions at home between 2021 and 2022.
Methods
The national hospital databases from the French statutory health insurance were used to identify all patients treated by ICI and to build a cohort of patients with at least one administration in Hospitalization At Home (HAH). All ICI administrations were collected retrospectively up to 2016. A descriptive analysis was performed to characterize patients, centers and "HAH patients" care pathways (based on treatment sequences clustering algorithms) and administration costs in the French statutory health insurance perspective.
Results
Over 2021 and 2022, 652 ICI (0.6%) patients were treated in HAH. Primary diagnosis among HAH patients were lung cancer with 51% (26%-78% depending on regions), followed by metastatic melanoma with 17%, (1%-18%). The three main regions were Ile de France (IDF), Auvergne Rhône Alpes (AURA) and Nouvelle Aquitaine (NA), with 543 patients (83% of HAH patients). The proportion of HAH patients per region varied from 0.1% to 1.6%. Mean age were similar between regions in main indications, from 65 to 69 years old in lung cancer regions and 68 in metastatic melanoma regions. Men proportion varied in lung cancer (6.6% - 31.8%) and were similar in metastatic melanoma (38.1% - 40.5%). Care pathways’ characteristics and costs per HAH infusion in main indications heavily differed per region (Table). Table: 91P
HAH patients’ and care pathways’ characteristics, and cost of HAH infusion, in the 3 main regions per indication
Regions | N | Mean Duration (±STD) 1st DCU - 1st HAH (days) | Mean Karnofsky Score (±STD) | Cost per infusion (€) | |
Lung | IDF | 80 | 346 (±378) | 57 (±7) | 314 (±213) |
AURA | 101 | 255 (±205) | 74 (±12) | 401 (±1480) | |
NA | 105 | 270 (±337) | 63 (±13) | 325 (±685) | |
France | 330 | 304 (±342) | 64 (±13) | 346 (±901) | |
Metastatic melanoma | IDF | 27 | 351 (±379) | 58 (±4) | 268 (±18) |
AURA | 27 | 513 (±523) | 73 (±8) | 311 (±113) | |
Occitanic | 6* | - | - | - | |
France | 69 | 381 (±433) | 64 (±10) | 290 (±86) |
STD: Standard Deviation * <11 patients : sample results not presented
Conclusions
Patient pathways depended on indication and differed according to regions. Further analyses on healthcare resources will allow to understand how optimizing HAH use for ICI patients in France.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
A.C. Toffart, G. Casanova: Financial Interests, Personal, Advisory Board: BMS. M. Pierre, H. Lemasson, V. Moreau-Mallet, M. Chartier: Financial Interests, Personal, Affiliate: BMS. N. Pagès, R. Jolivel, A. Panès: Financial Interests, Personal, Financially compensated role: BMS. M. Pérol: Financial Interests, Personal, Advisory Board, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen, Novocure, AbbVie, Anheart Therapeutics, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker, Symposium: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Personal, Advisory Board, Expert Testimony: AstraZeneca; Financial Interests, Personal, Steering Committee Member, Steering Committee Member: Lilly; Financial Interests, Institutional, Local PI, Local PI: AbbVie, Amgen, Anheart Therapeutics, Apollomics, Arrivent Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Innate Pharma, Roche; Financial Interests, Institutional, Research Grant, Research Grant: AstraZeneca, Boehringer Ingelheim, Roche, Takeda; Financial Interests, Personal, Trial Chair, Trial Chair: Anheart Therapeutics; Financial Interests, Personal, Steering Committee Member, Idmc Chair: PharmaMar, Sophiagenetics; Financial Interests, Personal, Steering Committee Member, Steering Committee Member: Roche; Financial Interests, Personal, Other, DMSB: Roche.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract